A5035685296- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Renal cell carcinoma treatment
- Melanoma and MAPK Pathways
- Urinary and Genital Oncology Studies
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- Phagocytosis and Immune Regulation
- Renal and related cancers
- Urological Disorders and Treatments
- Tissue Engineering and Regenerative Medicine
- Multiple and Secondary Primary Cancers
- Advanced Breast Cancer Therapies
- Virus-based gene therapy research
- Cancer Cells and Metastasis
- Esophageal Cancer Research and Treatment
- Eosinophilic Disorders and Syndromes
- Ferroptosis and cancer prognosis
- Cell Adhesion Molecules Research
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
Xinxiang Medical University
2025
Peking University
2016-2025
Peking University Cancer Hospital
2016-2025
First Hospital of China Medical University
2024
China Medical University
2024
Jilin Electric Power Research Institute (China)
2024
Ministry of Education
2022
Washington University in St. Louis
2015
TCM-Intigrated Cancer Center of Southern Medical University
2015
General Hospital of Shenyang Military Region
2014
Melanomas harbor aberrations in the c-Kit gene. We tested efficiency of tyrosine kinase inhibitor imatinib selected patients with metastatic melanoma harboring mutations or amplifications.Forty-three were enrolled on this phase II trial. Each patient received a continuous dose 400 mg/d unless intolerable toxicities disease progression occurred. Fifteen who experienced allowed to escalate 800 mg/d.Forty-three eligible for evaluation, and median follow-up time was 12.0 months. The...
Malignant melanoma is a rare disease in Asia, and knowledge on its characteristics clinical outcome Asian patients limited. The purpose of this observational study was to determine the presentation with China.A database prospectively established for analysis. elements included basic demographic data prognosticators previously reported literature, as well follow-up including after treatment. Medical record all pathologically diagnosed malignant consulted our center since 2006 were retrieved...
KIT aberrations were described in acral and mucosal melanomas largely Caucasian populations. Asian populations are more prone to develop than cutaneous melanomas, may harbor a high frequency of aberrations.Melanoma subtypes (n = 502) analyzed histologically determine melanoma subtype. Tissue samples for mutations exons 9, 11, 13, 17, 18 gene genomic DNA by PCR amplification Sanger sequencing. The copy numbers the quantitative PCR, protein expression levels (CD117) determined...
Abstract Purpose: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E, in patients HER2+ locally advanced or metastatic urothelial carcinoma (mUC) refractory to standard therapies. Patients Methods: This was phase II, open-label, multicenter, single-arm study (IHC status 3+ 2+) mUC who previously failed at least one line systemic chemotherapy. The primary endpoint objective response rate (ORR) assessed by blinded...
Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory either therapy alone.We conducted a single-center, phase IB trial evaluating safety preliminary efficacy toripalimab, humanized immunoglobulin G4 monoclonal...
Abstract Purpose RC48 contains the novel humanized anti-HER2 antibody hertuzumab conjugated to MMAE via a cleavable linker. A phase I study was initiated evaluate toxicity, MTD, PK, and antitumor activity of in patients with HER2-overexpressing locally advanced or metastatic solid carcinomas, particularly gastric cancer. Patients methods This 2-part study. Successive cohorts received escalating doses (0.1 mg/kg, 0.5 1.0 2.0 2.5 3.0 mg/kg). Dose expansion proceeded at dose mg/kg Q2W. The...
To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E, in patients HER2-positive locally advanced or metastatic urothelial carcinoma (UC) refractory to standard regular therapies.
Mucosal melanoma is rare and associated with extremely poor prognosis. However, standard adjuvant therapy for mucosal has not been established. We conducted a randomized phase II clinical trial in patients resected to compare the efficacy safety of high-dose IFN-α2b (HDI) temozolomide-based chemotherapy as therapy.Patients stage II/III after surgery were into three groups: observation group (group A, alone), HDI B, treated 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 U IFN-α2b), temozolomide...
Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T therapy treatment other solid tumors has been limited. We incorporated 4-1BB into anti-GD2 to test their cytotoxicity melanoma vitro and vivo. Moreover, we reported expression ganglioside GD2 non-Caucasian populations for first time, thus providing a basis future research. This study included tumor samples from 288 at Peking...
JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate safety, tolerability, clinical activity JS001 advanced melanoma or urologic cancer patients who are refractory standard systemic therapy. In dose escalation cohorts, subjects initially received single-dose, intravenous infusion were followed for 28 days by...
Purpose: Effective therapies for the majority of metastatic acral melanoma patients have not been established. Thus, we investigated genetic aberrations CDK4 pathway in and evaluated efficacy CDK4/6 inhibitors targeted therapy melanoma.Experimental Design: A total 514 primary samples were examined copy number variations (CNV) pathway-related genes, including Cdk4, Ccnd1, P16INK4a , by QuantiGenePlex DNA Assay. The sensitivity established cell lines patient-derived xenograft (PDX) containing...
PD-1 checkpoint blockade immunotherapy induces long and durable response in patients with advanced melanoma. However, only a subset of melanoma benefit from this approach. The mechanism triggering the innate resistance anti-PD-1 therapy remains unclear.Experimental Design: Whole-exome sequencing (WES) RNA (RNA-Seq) analyses were performed training cohort (n = 31) using baseline tumor biopsies treated antibody. Copy-number variations (CNVs) for genes CDK4, CCND1, CDKN2A assayed TaqMan...
Immune checkpoint inhibitor (ICI) treatments produce clinical benefit in many patients. However, better pretreatment predictive biomarkers for ICI are still needed to help match individual patients the treatment most likely be of benefit. Existing gene expression profiling (GEP)-based primarily focused on measuring a T cell-inflamed tumor microenvironment that contributes positively response ICI. Here, we identified an immunosuppression signature (IMS) through analyzing RNA sequencing data...
Mucosal melanoma is an aggressive subtype with poor response to antiprogrammed cell death-1 (PD-1) monotherapy. Axitinib in combination toripalimab, a humanized IgG4 mAb against PD-1, showed promising rate patients metastatic mucosal (MM) phase Ib study. Here, we report the updated overall survival (OS), duration of (DoR), and biomarker analysis results.Patients advanced MM received toripalimab 1 or 3 mg/kg intravenously every 2 weeks combined axitinib 5 mg orally two times per day until...
Nectin-4 is an emerging biomarker for cancer diagnosis and therapy. Recently, enfortumab vedotin (EV) was approved by the FDA as first nectin-4 targeting antibody-drug conjugate treating advanced urothelial carcinoma (UC). A PET imaging method to noninvasively quantify expression level would potentially help select patients most likely respond EV predict response.In this study, we designed a bicyclic peptide-based radiotracer 68Ga-N188. Initially, performed preclinical evaluations of...
•Toripalimab plus axitinib provided significantly better PFS than sunitinib as a first-line treatment for advanced RCC.•A higher ORR was found in patients who received toripalimab those sunitinib.•The combination of generally well tolerated.•No new safety signals were identified the outside known profile or axitinib. BackgroundImmune checkpoint inhibitors with tyrosine kinase are standard treatments clear cell renal carcinoma (RCC). This phase III RENOTORCH study compared efficacy and versus...
BackgroundThe outcome of patients with resectable mucosal melanoma is poor. Toripalimab combined axitinib has shown impressive results in metastatic an objective response rate 48.3% and a median progression free survival 7.5 months phase 1b trial. It was hypothesized that this combination administered the neoadjuvant setting might induce pathologic melanoma, so we conducted trial.Patients methodsThis single-arm II trial enrolled melanoma. Patients received toripalimab 3 mg/kg Q2W plus 5 mg...
Endostatin is a potent endogenous angiogenic inhibitor with implicated antitumor activity. However, efficacy of recombinant human endostatin (rhES) in clinical trials controversial, and application rhES treatment metastatic melanoma awaits further investigations. This phase II trial evaluated the safety soluble stable (Endostar) plus dacarbazine patients melanomas that contains no mutations c-kit BRAF genes. A total 110 received placebo (250 mg/m², n = 54) or Endostar (7.5 mg/m²) 56). The...
Purpose: Ethnic differences are conspicuous in melanoma. This study is to obtain a comprehensive view of genomic landscape and better understanding the correlations gene mutation status with clinicopathologic characteristics disease prognosis Asian population.Experimental Design: A total 2,793 melanoma patient samples were retrospectively collected analyzed for mutations C-KIT, BRAF, NRAS, PDGFRA coding regions telomerase reverse transcriptase (TERT) promoter region by Sanger sequencing....
Abstract Purpose: mTOR is a validated target in cancer. It remains to be determined whether melanoma patients bearing mutation could selected for treatment with PI3K–AKT–mTOR pathway inhibitors. Experimental Design: A total of 412 samples were included. Gene aberrations all exons detected by Sanger sequencing and confirmed using Agilent's SureSelect Target Enrichment System. HEK293T cells stably expressing mutants constructed transcription activator-like effector nucleases technique....
Mucosal melanoma (MM) is the second most common subtype in Asian populations. Deregulation of microRNAs (miRNAs) has been extensively investigated various cancers, including cutaneous melanoma. However, roles miRNAs MM are unclear. In this study, we carried out miRNA profiling MM, and clinical biological miR-23a-3p MM. Methods: expression was profiled by microarray analysis. The quantitated qRT-PCR a cohort 117 patients with its prognostic significance evaluated. effect demonstrated both...
Abstract Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers predicting response remain to be explored. This study aims evaluate safety, efficacy, and correlative biomarker of toripalimab in previously treated mUC. Patients Methods: mUC received 3 mg/kg Q2W. Clinical was assessed every 8 weeks by an independent review committee per RECIST v1.1. Tumor PD-L1 expression, tumor mutational...